HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · Real-Time Price · USD
2.170
+0.130 (6.37%)
At close: Jan 24, 2025, 4:00 PM
2.180
+0.010 (0.46%)
After-hours: Jan 24, 2025, 4:15 PM EST
HOOKIPA Pharma Employees
As of December 31, 2023, HOOKIPA Pharma had 179 total employees, including 151 full-time and 28 part-time employees. The number of employees increased by 1 or 0.56% compared to the previous year.
Employees
179
Change (1Y)
1
Growth (1Y)
0.56%
Revenue / Employee
$279,324
Profits / Employee
-$242,296
Market Cap
26.16M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
HOOK News
- 16 days ago - Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA - GlobeNewsWire
- 17 days ago - HOOKIPA Pharma Inc - FORM 8 (OPD) - GlobeNewsWire
- 18 days ago - HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - GlobeNewsWire
- 20 days ago - HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment - GlobeNewsWire
- 24 days ago - Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - GlobeNewsWire